Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy
Author:
Affiliation:
1. Division of Medical Oncology; Mayo Clinic; Rochester Minnesota USA
2. Department of Immunology; Mayo Clinic; Rochester Minnesota USA
3. Department of Urology; Mayo Clinic; Rochester Minnesota USA
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Reference6 articles.
1. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N. Engl. J. Med.,2015
2. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion;Dong;Nat. Med.,1999
3. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma;Frigola;Clin. Cancer Res.,2011
4. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer;McLaughlin;JAMA Oncol.,2015
5. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies;Ilie;Ann. Oncol.,2016
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics;Clinical Cancer Research;2022-11-30
2. Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy;Cancers;2021-08-25
3. EGFR Status Assessment for Better Care of Early Stage Non-Small Cell Lung Carcinoma: What Is Changing in the Daily Practice of Pathologists?;Cells;2021-08-21
4. Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges;Cancers;2020-10-29
5. ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance;OncoImmunology;2020-01-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3